Please confirm you are human (Sign Up for free to never see this)
← Back to Search
Fundamental Mechanisms Of Immune Checkpoint Blockade Therapy.
S. Wei, Colm R Duffy, J. Allison
Published 2018 · Medicine
Save to my Library
Download PDFAnalyze on Scholarcy
Immune checkpoint blockade is able to induce durable responses across multiple types of cancer, which has enabled the oncology community to begin to envision potentially curative therapeutic approaches. However, the remarkable responses to immunotherapies are currently limited to a minority of patients and indications, highlighting the need for more effective and novel approaches. Indeed, an extraordinary amount of preclinical and clinical investigation is exploring the therapeutic potential of negative and positive costimulatory molecules. Insights into the underlying biological mechanisms and functions of these molecules have, however, lagged significantly behind. Such understanding will be essential for the rational design of next-generation immunotherapies. Here, we review the current state of our understanding of T-cell costimulatory mechanisms and checkpoint blockade, primarily of CTLA4 and PD-1, and highlight conceptual gaps in knowledge.Significance: This review provides an overview of immune checkpoint blockade therapy from a basic biology and immunologic perspective for the cancer research community. Cancer Discov; 8(9); 1069-86. ©2018 AACR.
This paper references
Shp-2 Is Dispensable for Establishing T Cell Exhaustion and for PD-1 Signaling In Vivo.
Giorgia Rota (2018)
Anti-CTLA-4 Antibodies of IgG2a Isotype Enhance Antitumor Activity through Reduction of Intratumoral Regulatory T Cells
Mark Selby (2013)
Acquired resistance to fractionated radiotherapy can be overcome by concurrent PD-L1 blockade.
S. Dovedi (2014)
PD‐1 inhibits T‐cell receptor induced phosphorylation of the ZAP70/CD3ζ signalosome and downstream signaling to PKCθ
K. Sheppard (2004)
Combination Therapy with Anti–CTLA-4 and Anti–PD-1 Leads to Distinct Immunologic Changes In Vivo
Rituparna Das (2015)
Oncology meets immunology: the cancer-immunity cycle.
D. Chen (2013)
An Abscopal Response to Radiation and Ipilimumab in a Patient with Metastatic Non–Small Cell Lung Cancer
E. Golden (2013)
Thymocyte development is normal in CTLA-4-deficient mice.
C. Chambers (1997)
Mouse Inducible Costimulatory Molecule (ICOS) Expression Is Enhanced by CD28 Costimulation and Regulates Differentiation of CD4+ T Cells1
A. Mcadam (2000)
Immune Cell Infiltration and Tertiary Lymphoid Structures as Determinants of Antitumor Immunity
V. Engelhard (2018)
Cutting Edge: Expression of Functional CD137 Receptor by Dendritic Cells1
R. Wilcox (2002)
Tumor immune profiling predicts response to anti-PD-1 therapy in human melanoma.
Adil I. Daud (2016)
Critical Role for CD103(+)/CD141(+) Dendritic Cells Bearing CCR7 for Tumor Antigen Trafficking and Priming of T Cell Immunity in Melanoma.
E. W. Roberts (2016)
Fulminant Myocarditis with Combination Immune Checkpoint Blockade.
D. Johnson (2016)
Induced expression of PD‐1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death.
Y. Ishida (1992)
Generation of T follicular helper cells is mediated by interleukin-21 but independent of T helper 1, 2, or 17 cell lineages.
R. Nurieva (2008)
Myc Cooperates with Ras by Programming Inflammation and Immune Suppression
R. Kortlever (2017)
VISTA, a novel mouse Ig superfamily ligand that negatively regulates T cell responses
L. Wang (2011)
New checkpoints in cancer immunotherapy
Ling Ni (2017)
Trans-Endocytosis of CD80 and CD86: A Molecular Basis for the Cell-Extrinsic Function of CTLA-4
O. Qureshi (2011)
CD27 is required for generation and long-term maintenance of T cell immunity
J. Hendriks (2000)
Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota
M. Vétizou (2015)
Rescue of exhausted CD8 T cells by PD-1–targeted therapies is CD28-dependent
A. Kamphorst (2017)
Cross-Talk between Activated Human NK Cells and CD4+ T Cells via OX40-OX40 Ligand Interactions1
A. Zingoni (2004)
Tissue expression of PD-L1 mediates peripheral T cell tolerance
M. Keir (2006)
Visualization of specific B and T lymphocyte interactions in the lymph node.
P. Garside (1998)
Expression and functional significance of an additional ligand for CTLA-4.
D. Lenschow (1993)
Programmed cell death 1 forms negative costimulatory microclusters that directly inhibit T cell receptor signaling by recruiting phosphatase SHP2
T. Yokosuka (2012)
Dual function of CTLA-4 in regulatory T cells and conventional T cells to prevent multiorgan autoimmunity
N. Jain (2010)
CTLA4 Blockade Broadens the Peripheral T-Cell Receptor Repertoire
L. Robert (2014)
Immune-mediated inhibition of metastases after treatment with local radiation and CTLA-4 blockade in a mouse model of breast cancer.
S. Demaria (2005)
Checkpoint blockade immunotherapy reshapes the high-dimensional phenotypic heterogeneity of murine intratumoural neoantigen-specific CD8+ T cells
M. Fehlings (2017)
Th1-specific cell surface protein Tim-3 regulates macrophage activation and severity of an autoimmune disease
L. Monney (2002)
The future of immune checkpoint therapy
P. Sharma (2015)
Immune Toxicities Elicted by CTLA-4 Blockade in Cancer Patients Are Associated with Early Diversification of the T-cell Repertoire.
D. Oh (2017)
CD27, a Member of the Tumor Necrosis Factor Receptor Superfamily, Activates NF-κB and Stress-activated Protein Kinase/c-Jun N-terminal Kinase via TRAF2, TRAF5, and NF-κB-inducing Kinase*
H. Akiba (1998)
PD-1 blockade induces responses by inhibiting adaptive immune resistance
P. Tumeh (2014)
Binding of phosphatidyl-inositol-3-OH kinase to CD28 is required for T-cell signalling
F. Pagès (1994)
CD4/major histocompatibility complex class II interaction analyzed with CD4‐ and lymphocyte activation gene‐3 (LAG‐3)‐Ig fusion proteins
B. Huard (1995)
LSECtin expressed on melanoma cells promotes tumor progression by inhibiting antitumor T-cell responses.
F. Xu (2014)
Cancer Immunotherapy with Immunomodulatory Anti-CD137 and Anti-PD-1 Monoclonal Antibodies Requires BATF3-Dependent Dendritic Cells.
A. R. Sánchez-Paulete (2016)
Distinct Cellular Mechanisms Underlie Anti-CTLA-4 and Anti-PD-1 Checkpoint Blockade
Spencer C. Wei (2017)
Overcoming resistance to checkpoint blockade therapy by targeting PI3Kγ in myeloid cells
O. D. Henau (2016)
CD27 Dissects Mature NK Cells into Two Subsets with Distinct Responsiveness and Migratory Capacity1
Y. Hayakawa (2006)
VISTA is an immune checkpoint molecule for human T cells.
J. L. Lines (2014)
Proliferation of PD-1+ CD8 T cells in peripheral blood after PD-1–targeted therapy in lung cancer patients
A. Kamphorst (2017)
Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice.
H. Nishimura (2001)
LAG-3, a novel lymphocyte activation gene closely related to CD4
F. Triebel (1990)
Cutting edge: lymphoproliferative disease in the absence of CTLA-4 is not T cell autonomous.
M. Bachmann (1999)
CTL mobilization to virus-infected tissue requires CD4+ T cell help
Y. Nakanishi (2009)
Cloning and expression of murine CD27: comparison with 4‐1BB, another lymphocyte‐specific member of the nerve growth factor receptor family
Loes A. Gravestein (1993)
A novel molecular interaction for the adhesion of follicular CD4 T cells to follicular DC
K. S. Boles (2009)
CD4(+)CD25(+) immunoregulatory T cells: gene expression analysis reveals a functional role for the glucocorticoid-induced TNF receptor.
R. McHugh (2002)
Characterization of the major histocompatibility complex class II binding site on LAG-3 protein.
B. Huard (1997)
Cutting Edge: CTLA-4 on Effector T Cells Inhibits In Trans
Emily Corse (2012)
Gut microbiome modulates response to anti–PD-1 immunotherapy in melanoma patients
V. Gopalakrishnan (2018)
Cancer Exome Analysis Reveals a T Cell Dependent Mechanism of Cancer Immunoediting
H. Matsushita (2012)
OX40 promotes Bcl-xL and Bcl-2 expression and is essential for long-term survival of CD4 T cells.
P. Rogers (2001)
FcγRs Modulate the Anti-tumor Activity of Antibodies Targeting the PD-1/PD-L1 Axis.
R. Dahan (2015)
The three Es of cancer immunoediting.
Gavin P Dunn (2004)
CD80 (B7-1) Binds Both CD28 and CTLA-4 with a Low Affinity and Very Fast Kinetics
P. van der Merwe (1997)
CTLA-4 Control over Foxp3+ Regulatory T Cell Function
K. Wing (2008)
PD-L1 on tumor cells is sufficient for immune evasion in immunogenic tumors and inhibits CD8 T cell cytotoxicity
Vikram R. Juneja (2017)
Defining CD8+ T cells that provide the proliferative burst after PD-1 therapy
S. J. Im (2016)
Activating Fc γ receptors contribute to the antitumor activities of immunoregulatory receptor-targeting antibodies
Yannick Bulliard (2013)
Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor.
H. Nishimura (1999)
Molecular signature of CD8+ T cell exhaustion during chronic viral infection.
E. Wherry (2007)
The surface protein TIGIT suppresses T cell activation by promoting the generation of mature immunoregulatory dendritic cells
X. Yu (2009)
Preoperative CTLA-4 Blockade: Tolerability and Immune Monitoring in the Setting of a Presurgical Clinical Trial
B. Carthon (2010)
Human B7-1 (CD80) and B7-2 (CD86) bind with similar avidities but distinct kinetics to CD28 and CTLA-4 receptors.
P. Linsley (1994)
Stimulation of CD25+CD4+ regulatory T cells through GITR breaks immunological self-tolerance
J. Shimizu (2002)
Negative Regulation of T Cell Homeostasis by Lymphocyte Activation Gene-3 (CD223)1
C. Workman (2005)
Host expression of PD-L1 determines efficacy of PD-L1 pathway blockade–mediated tumor regression
H. Lin (2018)
Immune checkpoint blockade: a common denominator approach to cancer therapy.
S. Topalian (2015)
Checkpoint Blockade Cancer Immunotherapy Targets Tumour-Specific Mutant Antigens
M. M. Gubin (2014)
B7-Dc, a New Dendritic Cell Molecule with Potent Costimulatory Properties for T Cells
S. Tseng (2001)
PD-L1 on host cells is essential for PD-L1 blockade–mediated tumor regression
H. Tang (2018)
Bioenergetic Insufficiencies Due to Metabolic Alterations Regulated by the Inhibitory Receptor PD-1 Are an Early Driver of CD8(+) T Cell Exhaustion.
B. Bengsch (2016)
Mouse TIGIT inhibits NK‐cell cytotoxicity upon interaction with PVR
N. Stanietsky (2013)
Identification of a human OX-40 ligand, a costimulator of CD4+ T cells with homology to tumor necrosis factor
W. Godfrey (1994)
The CD40-TRAF6 axis controls affinity maturation and the generation of long-lived plasma cells
Cory L. Ahonen (2002)
CTLA-4 can function as a negative regulator of T cell activation.
T. Walunas (1994)
Engagement of the Pd-1 Immunoinhibitory Receptor by a Novel B7 Family Member Leads to Negative Regulation of Lymphocyte Activation
G. Freeman (2000)
Induction of Cytotoxic T Lymphocyte Antigen 4 (Ctla-4) Restricts Clonal Expansion of Helper T Cells
A. Doyle (2001)
PD-L2 is a second ligand for PD-1 and inhibits T cell activation
Yvette Latchman (2001)
Expression and function of 4-1BB and 4-1BB ligand on murine dendritic cells.
T. Futagawa (2002)
Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti–CTLA-4 therapy against melanoma
Tyler R. Simpson (2013)
Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses.
M. Butte (2007)
CD28-independent, TRAF2-dependent Costimulation of Resting T Cells by 4-1BB Ligand
Katina Saoulli (1998)
Functional CD40 antigen on B cells, dendritic cells and fibroblasts.
J. Banchereau (1995)
Anti–CTLA-4 therapy broadens the melanoma-reactive CD8+ T cell response
P. Kvistborg (2014)
Maturation and Activation of Dendritic Cells Induced by Lymphocyte Activation Gene-3 (CD223)1
S. Andreae (2002)
CTLA-4 engagement inhibits IL-2 accumulation and cell cycle progression upon activation of resting T cells
M. Krummel (1996)
B7-1 and B7-2 selectively recruit CTLA-4 and CD28 to the immunological synapse.
Tsvetelina Pentcheva-Hoang (2004)
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma.
J. Larkin (2015)
Specificity and affinity of human Fcgamma receptors and their polymorphic variants for human IgG subclasses.
P. Bruhns (2009)
Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study.
M. Overman (2017)
Nivolumab and ipilimumab versus ipilimumab in untreated melanoma.
Michael A. Postow (2015)
Blockade of CTLA-4 on CD4+CD25+ Regulatory T Cells Abrogates Their Function In Vivo1
Simon Read (2006)
Cloning of B7-2: a CTLA-4 counter-receptor that costimulates human T cell proliferation.
G. Freeman (1993)
CTLA-4 blockade increases IFNγ-producing CD4+ICOShi cells to shift the ratio of effector to regulatory T cells in cancer patients
C. Liakou (2008)
CD4+ regulatory T cells require CTLA-4 for the maintenance of systemic tolerance
R. Friedline (2009)
Early B cell changes predict autoimmunity following combination immune checkpoint blockade
Rituparna Das (2018)
Commensal Bifidobacterium promotes antitumor immunity and facilitates anti–PD-L1 efficacy
Ayelet Sivan (2015)
The third group of the B7‐CD28 immune checkpoint family: HHLA2, TMIGD2, B7x, and B7‐H3
M. Janakiram (2017)
Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma
Diana Miao (2018)
Inducible T cell antigen 4-1BB. Analysis of expression and function.
K. Pollok (1993)
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
R. Herbst (2014)
Tim-3 marks human natural killer cell maturation and suppresses cell-mediated cytotoxicity.
L. Ndhlovu (2012)
Pooled Analysis Safety Profile of Nivolumab and Ipilimumab Combination Therapy in Patients With Advanced Melanoma.
M. Sznol (2017)
CEACAM1 regulates TIM-3-mediated tolerance and exhaustion
Yu-Hwa Huang (2015)
Structural basis for cancer immunotherapy by the first-in-class checkpoint inhibitor ipilimumab
U. Ramagopal (2017)
Epigenetic stability of exhausted T cells limits durability of reinvigoration by PD-1 blockade
Kristen E. Pauken (2016)
CTLA-4-Mediated inhibition of early events of T cell proliferation.
M. C. Brunner (1999)
Cutting Edge: TIGIT Has T Cell-Intrinsic Inhibitory Functions
Nicole Joller (2011)
Genetic basis for clinical response to CTLA-4 blockade in melanoma.
A. Snyder (2014)
Immune-checkpoint proteins VISTA and PD-1 nonredundantly regulate murine T-cell responses
J. Liu (2015)
Access of protective antiviral antibody to neuronal tissues requires CD4 T cell help
N. Iijima (2016)
Melanoma Cell-Intrinsic PD-1 Receptor Functions Promote Tumor Growth
S. Kleffel (2015)
Identification of a new member of the tumor necrosis factor family and its receptor, a human ortholog of mouse GITR
A. Gurney (1999)
The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity
C. Zhu (2005)
Uncovering of functional alternative CTLA-4 counter-receptor in B7-deficient mice.
G. Freeman (1993)
Cancer immunotherapy using checkpoint blockade
A. Ribas (2018)
Vstm3 is a member of the CD28 family and an important modulator of T‐cell function
S. D. Levin (2011)
Molecular and biological characterization of a ligand for CD27 defines a new family of cytokines with homology to tumor necrosis factor
R. Goodwin (1993)
B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion
H. Dong (1999)
Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4.
E. Tivol (1995)
Negative regulators of T‐cell activation: potential targets for therapeutic intervention in cancer, autoimmune disease, and persistent infections
Tsvetelina Pentcheva-Hoang (2009)
Coinhibitory Pathways in the B7-CD28 Ligand-Receptor Family.
F. Schildberg (2016)
CTLA-4 is a second receptor for the B cell activation antigen B7
P. Linsley (1991)
Genomic Features of Response to Combination Immunotherapy in Patients with Advanced Non-Small-Cell Lung Cancer
M. Hellmann (2018)
The costimulation-regulated duration of PKB activation controls T cell longevity
Jianxun Song (2004)
Human plasmacytoid predendritic cells activate NK cells through glucocorticoid-induced tumor necrosis factor receptor-ligand (GITRL).
S. Hanabuchi (2006)
CTLA-4 and PD-1 Receptors Inhibit T-Cell Activation by Distinct Mechanisms
R. Parry (2005)
Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma.
D. Schadendorf (2015)
Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy
P. Sharma (2017)
PD-L1 and PD-L2 are differentially regulated by Th1 and Th2 cells
P'ng Loke (2003)
Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma.
A. Ribas (2013)
ICOS Ligation Recruits the p50α PI3K Regulatory Subunit to the Immunological Synapse1
Camille Fos (2008)
Chromatin states define tumor-specific T cell dysfunction and reprogramming
Mary Philip (2017)
Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
D. Le (2017)
Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti–CTLA-4 antibodies
K. Peggs (2009)
Deletion of CTLA-4 on regulatory T cells during adulthood leads to resistance to autoimmunity
A. Paterson (2015)
Tumor-Residing Batf3 Dendritic Cells Are Required for Effector T Cell Trafficking and Adoptive T Cell Therapy.
Stefani Spranger (2017)
The epigenetic landscape of T cell exhaustion
D. Sen (2016)
T Cell/Transmembrane, Ig, and Mucin-3 Allelic Variants Differentially Recognize Phosphatidylserine and Mediate Phagocytosis of Apoptotic Cells
R. Dekruyff (2010)
ICOS Controls the Pool Size of Effector-Memory and Regulatory T Cells1
Y. Burmeister (2008)
Improved Survival with T Cell Clonotype Stability After Anti–CTLA-4 Treatment in Cancer Patients
E. Cha (2014)
CD80 (B7) and CD86 (B70) provide similar costimulatory signals for T cell proliferation, cytokine production, and generation of CTL.
L. Lanier (1995)
Comprehensive analysis of the clinical immuno-oncology landscape
J. Tang (2018)
A reappraisal of CTLA-4 checkpoint blockade in cancer immunotherapy
Xuexiang Du (2018)
T-cell invigoration to tumour burden ratio associated with anti-PD-1 response
A. Huang (2017)
PD-1 alters T-cell metabolic reprogramming by inhibiting glycolysis and promoting lipolysis and fatty acid oxidation
N. Patsoukis (2015)
SHP-1 and SHP-2 Associate with Immunoreceptor Tyrosine-Based Switch Motif of Programmed Death 1 upon Primary Human T Cell Stimulation, but Only Receptor Ligation Prevents T Cell Activation1
J. Chemnitz (2004)
CD40 Stimulation Obviates Innate Sensors and Drives T Cell Immunity in Cancer.
Katelyn T. Byrne (2016)
De Novo Epigenetic Programs Inhibit PD-1 Blockade-Mediated T Cell Rejuvenation
Hazem E. Ghoneim (2017)
Anti-CTLA-4 therapy results in higher CD4+ICOShi T cell frequency and IFN-γ levels in both nonmalignant and malignant prostate tissues
H. Chen (2009)
Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab
N. Chaput (2017)
PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors
M. Curran (2010)
Expansion and Activation of CD103(+) Dendritic Cell Progenitors at the Tumor Site Enhances Tumor Responses to Therapeutic PD-L1 and BRAF Inhibition.
Hélène Salmon (2016)
Regulatory T Cells in Tumor-Associated Tertiary Lymphoid Structures Suppress Anti-tumor T Cell Responses.
N. Joshi (2015)
Disruption of the immune-checkpoint VISTA gene imparts a proinflammatory phenotype with predisposition to the development of autoimmunity
L. Wang (2014)
The blockade of immune checkpoints in cancer immunotherapy
D. Pardoll (2012)
Tumor-infiltrating DCs suppress nucleic acid–mediated innate immune responses through interactions between the receptor TIM-3 and the alarmin HMGB1
S. Chiba (2012)
Agonistic CD40 Antibodies and Cancer Therapy
R. Vonderheide (2013)
Cutting Edge: Molecular Analysis of the Negative Regulatory Function of Lymphocyte Activation Gene-31
C. Workman (2002)
Coinhibitory receptor PD-1H preferentially suppresses CD4⁺ T cell-mediated immunity.
D. Flies (2014)
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency.
D. Le (2015)
The immunoreceptor TIGIT regulates antitumor and antiviral CD8(+) T cell effector function.
Robert J. Johnston (2014)
ICOS receptor instructs T follicular helper cell versus effector cell differentiation via induction of the transcriptional repressor Bcl6.
Youn Soo Choi (2011)
CD28/B7 system of T cell costimulation.
D. Lenschow (1996)
Inducible costimulator (ICOS) potentiates TCR-induced calcium flux by augmenting PLCγ1 activation and actin remodeling.
Julien Leconte (2016)
Colon Immune-Related Adverse Events: Anti-CTLA-4 and Anti-PD-1 Blockade Induce Distinct Immunopathological Entities
C. Coutzac (2017)
Sequential administration of nivolumab and ipilimumab with a planned switch in patients with advanced melanoma (CheckMate 064): an open-label, randomised, phase 2 trial.
J. Weber (2016)
Tumor Mutational Burden and Response Rate to PD-1 Inhibition.
M. Yarchoan (2017)
Ipilimumab-dependent cell-mediated cytotoxicity of regulatory T cells ex vivo by nonclassical monocytes in melanoma patients
E. Romano (2015)
Mitochondrial Dynamics Controls T Cell Fate through Metabolic Programming
M. D. Buck (2016)
Tumor Necrosis Factor Receptor (TNFR)-associated Factor 5 Is a Critical Intermediate of Costimulatory Signaling Pathways Triggered by Glucocorticoid-induced TNFR in T Cells*
E. Esparza (2006)
Fc Effector Function Contributes to the Activity of Human Anti-CTLA-4 Antibodies
F. Arce Vargas (2018)
Cytotoxic T lymphocyte antigen-4 accumulation in the immunological synapse is regulated by TCR signal strength.
J. Egen (2002)
T cell costimulatory receptor CD28 is a primary target for PD-1–mediated inhibition
Enfu Hui (2017)
Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes.
Y. Agata (1996)
Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal‐Cell Carcinoma
R. Motzer (2018)
ICOS:ICOS-ligand interaction is required for type 2 innate lymphoid cell function, homeostasis, and induction of airway hyperreactivity.
H. Maazi (2015)
Akt provides the CD28 costimulatory signal for up-regulation of IL-2 and IFN-γ but not TH2 cytokines
L. Kane (2001)
TIGIT and PD-1 impair tumor antigen-specific CD8⁺ T cells in melanoma patients.
Joe-Marc Chauvin (2015)
Lymphoproliferative Disorders with Early Lethality in Mice Deficient in Ctla-4
P. Waterhouse (1995)
Epigenomic‐Guided Mass Cytometry Profiling Reveals Disease‐Specific Features of Exhausted CD8 T Cells
B. Bengsch (2018)
Tremelimumab in Combination with Exemestane in Patients with Advanced Breast Cancer and Treatment-Associated Modulation of Inducible Costimulator Expression on Patient T Cells
R. Vonderheide (2010)
Long term survival with cytotoxic T lymphocyte-associated antigen 4 blockade using tremelimumab.
Z. Eroglu (2015)
Antigens of activated rat T lymphocytes including a molecule of 50,000 Mr detected only on CD4 positive T blasts.
D. Paterson (1987)
Functional expression of CD134 by neutrophils
R. Baumann (2004)
Distinct contributions of different CD40 TRAF binding sites to CD154‐induced dendritic cell maturation and IL‐12 secretion
M. Mackey (2003)
VISTA is an inhibitory immune checkpoint that is increased after ipilimumab therapy in patients with prostate cancer
Jianjun Gao (2017)
Restoring function in exhausted CD8 T cells during chronic viral infection
D. Barber (2006)
The interaction of TIGIT with PVR and PVRL2 inhibits human NK cell cytotoxicity
N. Stanietsky (2009)
T-cell co-stimulation through B7RP-1 and ICOS
S. K. Yoshinaga (1999)
Systemic Immunity Is Required for Effective Cancer Immunotherapy
Matthew H. Spitzer (2017)
Ox-40 ligand: a potent costimulatory molecule for sustaining primary CD4 T cell responses.
I. Gramaglia (1998)
Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors
B. Routy (2018)
Genomic correlates of response to CTLA-4 blockade in metastatic melanoma
E. V. Van Allen (2015)
T cell exhaustion
E. Wherry (2011)
Neoadjuvant PD‐1 Blockade in Resectable Lung Cancer
P. Forde (2018)
CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation
M. Krummel (1995)
Radiation and Dual Checkpoint Blockade Activates Non-Redundant Immune Mechanisms in Cancer
Christina Twyman-Saint Victor (2015)
A new member of the tumor necrosis factor/nerve growth factor receptor family inhibits T cell receptor-induced apoptosis.
G. Nocentini (1997)
Identification of a Novel Activation-inducible Protein of the Tumor Necrosis Factor Receptor Superfamily and Its Ligand*
B. Kwon (1999)
cDNA sequences of two inducible T-cell genes.
B. Kwon (1989)
Nivolumab plus ipilimumab in advanced melanoma.
J. Wolchok (2013)
CTLA-4: new insights into its biological function and use in tumor immunotherapy
J. Egen (2002)
Long-term survival for patients with non-small-cell lung cancer with intratumoral lymphoid structures.
M. Dieu-Nosjean (2008)
Increased Frequency of ICOS+ CD4 T Cells as a Pharmacodynamic Biomarker for Anti-CTLA-4 Therapy
D. Ng Tang (2013)
Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis
J. Moslehi (2018)
This paper is referenced by
Pre-clinical studies of EC2629, a highly potent folate- receptor-targeted DNA crosslinking agent
J. Reddy (2020)
Bioactive Nanoparticles for Cancer Immunotherapy
Suchithra Poilil Surendran (2018)
Mistletoe and Immunomodulation: Insights and Implications for Anticancer Therapies
Shiao Li Oei (2019)
The immunogenic potential of recurrent cancer drug resistance mutations: an in silico study
Marco Punta (2019)
Treg programming and therapeutic reprogramming in cancer
M. M. Moreno Ayala (2019)
Multimodel preclinical platform predicts clinical response of melanoma to immunotherapy
Eva Pérez-Guijarro (2020)
Cancer-associated fibroblasts: how do they contribute to metastasis?
M. Kwa (2019)
Engineered nanoparticles circumvent the adaptive treatment tolerance to immune-checkpoint blockade therapy
W. Guo (2019)
AP-1 Transcription Factors as Regulators of Immune Responses in Cancer
Vasileios Atsaves (2019)
Whole-genome sequencing identifies responders to Pembrolizumab in relapse/refractory natural-killer/T cell lymphoma
J. Q. Lim (2020)
Dissecting genetic determinants of variation in human immune responses.
O. Tong (2020)
Safety and efficacy of sintilimab combined with oxaliplatin/capecitabine as first-line treatment in patients with locally advanced or metastatic gastric/gastroesophageal junction adenocarcinoma in a phase Ib clinical trial
Haiping Jiang (2020)
CAR T Cell Therapy Progress and Challenges for Solid Tumors.
Lawrence A Stern (2020)
Breaking Bottlenecks for the TCR Therapy of Cancer
Lena Gaissmaier (2020)
Inhibition of Colony-Stimulating Factor-1 Receptor Enhances the Efficacy of Radiotherapy and Reduces Immune Suppression in Glioblastoma
Muayad F. Almahariq (2021)
Tumor-associated carbohydrates and immunomodulatory lectins as targets for cancer immunotherapy
Natália Rodrigues Mantuano (2020)
Overcoming resistance to anti-PD1 and anti-PD-L1 treatment in gastrointestinal malignancies
Alberto Puccini (2020)
A PSMA-Targeting CD3 Bispecific Antibody Induces Antitumor Responses that Are Enhanced by 4-1BB Costimulation
Danica Chiu (2020)
Hyperprogression after immunotherapy: A comprehensive review.
Muharrem Okan Cakir (2019)
Characterization of human cancer xenografts in humanized mice
Jonathan Rios-Doria (2020)
The Soluble Isoform of CTLA-4 Correlates with Interferon-α Activity in Systemic Lupus Erythematosus
L. N. Dahal (2020)
Decoding the Role of Interleukin-30 in the Crosstalk between Cancer and Myeloid Cells
Emma Di Carlo (2020)
Epidermal activation of Hedgehog signaling establishes an immunosuppressive microenvironment in basal cell carcinoma by modulating skin immunity
Sandra Grund-Gröschke (2019)
From Super-Enhancer Non-coding RNA to Immune Checkpoint: Frameworks to Functions
Manqing Wu (2019)
The Emerging Role of Exosomes in Diagnosis, Prognosis, and Therapy in Head and Neck Cancer
Linda Hofmann (2020)
Transient activation of tumoral DNA damage tolerance pathway coupled with immune checkpoint blockade exerts durable tumor regression in mouse melanoma.
Ming Zhuo (2020)
Immunotherapy for mesothelioma: a critical review of current clinical trials and future perspectives.
S. Gray (2020)
PD-L1 on dendritic cells attenuates T cell activation and regulates response to immune checkpoint blockade
Qi Peng (2020)
Tumor-Infiltrating Lymphocytes and Their Prognostic Value in Cutaneous Melanoma
Fabienne Maibach (2020)
Antibody therapeutics and immunoregulation in cancer and autoimmune disease.
M. Yasunaga (2019)
Failure Mode and Effects Analysis (FMEA) for immunogenicity of therapeutic proteins.
N. Chirmule (2020)
Cholangiocarcinoma 2020: the next horizon in mechanisms and management
J. Banales (2020)See more